Latest Financial Results

Q1 2017

Quarterly Results

Mar 31, 2017

Stock Information

Symbol

OTCQB: NSPX

Price

Loading...

Change

Loading...

Market Cap

Loading...

Volume

Loading...

Company Overview

Inspyr Therapeutics, Inc. is a Los Angeles-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. Inspyr's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

IR Contact Information

Investor Relations
Lisa Cali
T: 408-239-7503
lcali@inspyrtx.com

Transfer Agent
American Stock Transfer and Trust Company
6201 15th Ave.
Brooklyn, NY 11219
T: (800) 937-5449
www.amstock.com

View All Contacts